Thermo Fisher Scientific (TMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2011 | 12-2010 | 09-2010 | 06-2010 | 03-2010 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,788,700 | 917,100 | 930,200 | 1,307,400 | 1,431,700 |
| Marketable Securities | 5,200 | 8,900 | 9,100 | 9,200 | 8,500 |
| Receivables | 1,565,500 | 1,473,800 | 1,562,100 | 1,472,500 | 1,493,800 |
| Inventories | 1,264,000 | 1,172,900 | 1,207,700 | 1,148,500 | 1,154,600 |
| Income taxes - deferred | 183,800 | 181,300 | 169,100 | 162,900 | 161,000 |
| Other current assets | 382,100 | 381,000 | 292,800 | 247,500 | 279,000 |
| TOTAL | $6,189,300 | $4,135,000 | $4,171,000 | $4,348,000 | $4,528,600 |
| Non-Current Assets | |||||
| PPE Net | 1,389,000 | 1,360,200 | 1,366,000 | 1,297,700 | 1,312,300 |
| Intangibles | 14,895,000 | 14,909,400 | 15,472,500 | 15,153,100 | 15,347,300 |
| Other Non-Current Assets | 957,300 | 944,800 | 527,500 | 482,100 | 436,400 |
| TOTAL | $17,241,300 | $17,214,400 | $17,366,000 | $16,932,900 | $17,096,000 |
| Total Assets | $23,430,600 | $21,349,400 | $21,537,000 | $21,280,900 | $21,624,600 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 616,900 | 546,700 | 581,900 | 568,500 | 596,100 |
| Accrued Expenses | 251,200 | 304,500 | 319,800 | 248,900 | 246,100 |
| TOTAL | $4,146,000 | $1,709,800 | $1,770,600 | $1,616,000 | $1,775,700 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,800,800 | 2,031,300 | 2,057,600 | 2,027,600 | 1,923,200 |
| Deferred Revenues | 193,200 | 158,200 | 165,500 | 163,800 | 167,800 |
| Other Non-Current Liabilities | 623,100 | 621,200 | 543,800 | 539,700 | 548,100 |
| TOTAL | $4,029,900 | $4,278,600 | $4,369,800 | $4,319,800 | $4,368,900 |
| Total Liabilities | $8,175,900 | $5,988,400 | $6,140,400 | $5,935,800 | $6,144,600 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 383,259 | 390,607 | 397,478 | 407,431 | 410,406 |
| Common Shares | 403,400 | 401,800 | 426,000 | 425,800 | 425,100 |
| Retained earnings | 5,638,600 | 5,386,400 | 5,088,900 | 4,820,400 | 4,583,100 |
| Other shareholders' equity | 164,300 | 44,100 | 78,800 | -150,000 | -47,400 |
| TOTAL | $15,254,700 | $15,361,000 | $15,396,600 | $15,345,100 | $15,480,000 |
| Total Liabilities And Equity | $23,430,600 | $21,349,400 | $21,537,000 | $21,280,900 | $21,624,600 |